2026 · 2nd Quarter (Apr 1 - June 30)

NOVARTIS

Filed by DLA PIPER LLP (US).

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 20, 2026
Income: $60,000.00
Expenses: Not reported
Registrant: DLA PIPER LLP (US)
Client: NOVARTIS
Filing UUID: b4fe403f-68f3-48c9-a48b-98fded7f646f
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

CPT · Copyright/Patent/Trademark

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

TAX · Taxation/Internal Revenue Code

Tax reform and tax policy.

TRD · Trade (domestic/foreign)

Tariffs and biotechnology issues related to Treasury and competition with China.

HCR · Health Issues

Issues relating to drug pricing and drug development policies. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act. Most Favored Nation (MFN) policy. Issues related to the 340B program.

Literal federal measure citations: H.R. 1492, S. 832, H.R. 1672

MMM · Medicare/Medicaid

Issues related to rare disease and treatment. Drug and pricing policies. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.